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Background: Marijuana is often smoked via a filterless cigarette and contains similar chemical makeup as smoked 
tobacco. There are few publications describing usage patterns and respiratory risks in older adults or in those with 
chronic obstructive pulmonary disease (COPD).
Methods: A cross-sectional analysis of current and former tobacco smokers from the Subpopulations and 
Intermediate Outcome Measures in COPD Study (SPIROMICS) study assessed associations between marijuana 
use and pulmonary outcomes. Marijuana use was defined as never, former (use over 30 days ago), or current 
(use within 30 days). Respiratory health was assessed using quantitative high-resolution computed tomography 
(HRCT) scans, pulmonary function tests and questionnaire responses about respiratory symptoms.
Results: Of the total 2304 participants, 1130 (49%) never, 982 (43%) former, and 192 (8%) current marijuana 
users were included. Neither current nor former marijuana use was associated with increased odds of wheeze (odds 
ratio [OR] 0.87, OR 0.97), cough (OR 1.22; OR 0.93) or chronic bronchitis (OR 0.87; OR 1.00) when compared 
to never users. Current and former marijuana users had lower quantitative emphysema (P=0.004, P=0.03), higher 
percent predicted forced expiratory volume in 1 second (FEV1%) (P<0.001, P<0.001), and percent predicted forced 
vital capacity (FVC%) (p<0.001, P<0.001). Current marijuana users exhibited higher total tissue volume (P=0.003) 
while former users had higher air trapping (P<0.001) when compared to never marijuana users.
Conclusions: Marijuana use was found to have little to no association with poor pulmonary health in older current 
and former tobacco smokers after adjusting for covariates. Higher forced expiratory volume in 1 second (FEV1) 
and forced vital capacity (FVC) was observed among current marijuana users. However, higher joint years was 
associated with more chronic bronchitis symptoms (e.g., wheeze), and this study cannot determine if long-term 
heavy marijuana smoking in the absence of tobacco smoking is associated with lung symptoms, airflow obstruction, 
or emphysema, particularly in those who have never smoked tobacco cigarettes.
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Introduction
Marijuana is typically consumed by burning ground 
flower, top leaves or bud (marijuana) in a filter-less 
cigarette or joint with or without tobacco and inhaling 
its smoke.1 Marijuana has a similar chemical makeup, 
including toxins, as smoked tobacco, aside from 
approximately 60 cannabinoids in marijuana and 
nicotine in tobacco.  Marijuana is typically smoked 
with larger inhaled volumes and much longer breath 
holding times than tobacco2 however, marijuana users 
generally smoke far fewer joints than tobacco smokers 
smoke cigarettes. The effects of smoking marijuana on 
lung health are controversial. In healthy individuals 
or those with asthma, a single episode of smoking a 
joint may lead to an acute bronchodilator response.3–5 
Contradicting these results, other studies have reported 
a higher prevalence of wheezing, cough and sputum 
(bronchitis) in marijuana users6,7; unlike the clear 
association between tobacco cigarette smoking and 
COPD, epidemiological data have reported conflicting 
associations between marijuana use and lung function. 
For example, some epidemiologic studies have found 
that marijuana use is associated with a reduction 
in the ratio of forced expiratory volume at 1 second 
(FEV1) to forced vital capacity (FVC) suggestive of 
obstructive lung disease.8,9 Other studies have reported 
mild increases in FVC,10–12 thought to be due to the 
deep breathing maneuvers of users, thus potentially 
accounting for a reduced FEV1/FVC, independent of 
obstructive lung disease.
There are significant challenges to assessing the role 
of marijuana on lung function, including the impact of 
co-existent tobacco smoking on respiratory outcomes. 
One population study looked at the role of marijuana 
use alone, or in combination with tobacco use, on 
lung function tests.6 Both marijuana and tobacco use 
alone were associated with a significant reduction in 
FEV1/FVC but when assessed for interaction between 
marijuana and tobacco smoking status they found 
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Population
SPIROMICS (ClinicalTrials.gov Identifier: NCT01969
344) is an ongoing multicenter prospective
observational study funded by the National Institutes
of Health (NIH)14 that enrolled 2982 individuals
between November 2011 and January 2015.
Individuals were recruited at university medical
centers, and were 40-80 years old at the time of
enrollment. The institutional review board at all sites
approved the study protocol. Individuals (N=2982)
were categorized as non-tobacco smokers (< 1 pack
year; stratum 1) or smokers (> 20 pack years; stratum
2-4). Study participants provided written informed
consent.
Participants were enrolled into 4 strata based on 
tobacco smoking history, post-bronchodilator FEV1/
FVC ratio, and other lung function criteria. The 
analyses reported here include participants (N=2304) 
with >20 pack years who completed a short survey 
regarding marijuana use at the first visit. Never 
smoking controls (<1 tobacco pack year history) were 
recruited and enrolled based on normal spirometric 
function and represent a non-random comparison 
group for marijuana exposure. Marijuana users in 
this group were known to have normal lung function 
at enrollment. Because of this recruitment bias, never 
tobacco-smoking controls (N=157) were excluded 
from the analysis. 
Methods
Assessment of Marijuana Use
Marijuana lifetime exposure and current use status 
were assessed at enrollment (online supplement Table 
1). Marijuana use was categorized into current (use 
in the past 30 days), and former (use over 30 days 
ago) users and compared to never users. Those with 
a history of marijuana use estimated the number of 
bowls or joint equivalents smoked per week and how 
many years the participant had smoked marijuana 
(one bowl was equated to one joint in this analysis). 
This information was used to calculate the number of 
joint years which was kept as a continuous variable; 1 
joint year is equivalent to smoking 1 joint or bowl per 
day for one year. A supplementary analysis was added 
to assess the impact of joint-year history with lung 
function and symptoms. Joint years were categorized 
into <10, 10-20, and >20 joint-year history and 
compared to those who reported zero joint years. 
Clinical Data and Definitions
Full details regarding the collection of clinical data 
have been described previously.14 COPD was defined 
as post-bronchodilator ratio of FEV1 to FVC < 0.70. 
We used Global initiative for chronic Obstructive 
Lung Disease (GOLD) guidelines15 to assess COPD 
severity as GOLD stages I-IV. Participants with FEV1/
FVC≥0.70 and FEV1<80% were classified as preserved 
ratio impaired spirometry (PRISm).16
Respiratory health questionnaires included: the 
modified Medical Research Council (mMRC) dyspnea 
score, the Short Form Health Survey--SF-36, and 
the St George’s Respiratory Questionnaire (SGRQ). 
Chronic bronchitis was defined as having 2 or more 
clinical criteria defined at their enrollment in the 
study. Acute exacerbations of respiratory disease were 
ascertained during the longitudinal follow-up (LFU) 
visit by asking “Since we last spoke, have you had an 
episode of increased cough and phlegm or shortness 
of breath, which lasted 48 hours or more?” If they 
answered yes, participants were further asked whether 
they received antibiotics or corticosteroids. Additional 
questions asked at each LFU contact included whether 
the participant urgently visited his/her doctor’s office, 
went to an emergency department, or was hospitalized. 
Participants were considered to have experienced an 
exacerbation if they answered yes to receiving either 
antibiotic and/or systemic corticosteroids. A severe 
exacerbation was a report of visiting an emergency 
department and/or hospitalization for an acute 
the effect of marijuana use in those who also smoked 
tobacco was to reduce this effect by 0.8% (95% 
confidence interval [CI] -1.8% to 3.4%).6 Similar results 
were found with FEV1 and maximum midexpiratory 
flow (MMEF). Tan et al reported no association of 
marijuana alone with spirometricly-defined COPD in a 
random sample of Canadian adults >age 40, but they 
did observe a significant interaction between marijuana 
and tobacco.12  Other significant limitations to most 
previous research include bias on studying younger 
individuals  (< 50 years of age) who are unlikely to 
show significant signs of lung disease even with 
significant tobacco exposure and few published studies 
have assessed emphysema by CT scan.6,13 To address 
some of these limitations we have investigated the 
relationship between self-reported marijuana use in the 
Subpopulations and Intermediate Outcomes in COPD 
Study (SPIROMICS) study.
episode of respiratory disease. The total number of 
exacerbations was the total number of events for which 
a participant received antibiotics and/or systemic 
steroids irrespective of treatment location. The 
interval time between assessments was 3 months. CT 
scans at total lung capacity (TLC) and residual volume 
(RV) were acquired at enrollment and at a 1-year 
return visit.17 CT phenotyping was done using VIDA 
software on segmented lung images to measure lung 
volumes derived from imaging at TLC and RV. Metrics 
at TLC included mean lung attenuation, total lung 
tissue volume, and percent lung voxels falling below 
a threshold of -950 (emphysema). At RV, the percent 
voxels falling below 856 Hounsfield units (HU) (air 
trapping) were assessed.  
Data Analysis
Cross-sectional analyses were conducted using R 
(version 3.3.1). Associations between respiratory 
symptoms and marijuana smoking status were 
examined using logistic regression adjusted for age, 
race, gender, FEV1%, current tobacco smoking status, 
pack years, and joint years. Pulmonary function 
testing variables and total tissue volume were kept 
as continuous variables and assessed with simple 
linear regression. Percent-predicted FEV1 and FVC 
were adjusted for gender, race, height2, age2, current 
tobacco smoking status, joint and pack years. All other 
pulmonary function variables were adjusted for height 
and age in addition to the covariates listed above. 
Additional analyses of the combined effect of current 
tobacco and marijuana use status on lung function 
were assessed for potential interactions and adjusted 
for age2, height2, joint, and pack years. Participants 
were further categorized as: current smokers of both 
tobacco and marijuana (TM), current smokers of 
marijuana and former tobacco smokers (MS), current 
smokers of tobacco and never marijuana smokers (TS), 
and never or former marijuana smokers and former 
tobacco smokers (NS). 
Emphysema severity was assessed with linear 
regression using stepwise selection; Akaike 
Information Criterion (AIC) is used to assign the most 
appropriate predictive covariates. Variables selected 
were age, gender, race, FEV1%, tobacco smoking status, 
joint years, pack years, and body mass index (BMI). 
Data Analysis: Assessment of Joint-Year History
Joint years were categorized into <10, 10-20, and >20 
Participant Characteristics
In a total of 2304 participants, 1130 (49%) never, 982 
(43%) former, and 192 (8%) current marijuana users 
are included. Participant characteristics are displayed 
in Table 1. Current marijuana users were more likely 
to be younger, white, and male than never users. They 
were also more likely to be current tobacco smokers and 
have less severe COPD. Joint years were significantly 
higher in current compared to former marijuana users, 
but there was a wide range in each group. BMI was 
significantly higher for former marijuana users when 
compared to never users. 
Participant Characteristics: Assessment of Joint Years
Further assessment of participant characteristics and 
joint years are included in the online supplement, 
Table 1b. Of the 2304 participants, 1610 (70%) had 
zero joint years, 388 (17%) had fewer than 10, 98 
participants (4%) had 10-20, and 208 (9%) had greater 
than 20 joint years. Higher joint-year history was 
associated with younger age, being male, and white. 
Higher joint years was also associated with current 
tobacco smoking (as opposed to a former smoker), but 
lower tobacco pack years. 
Results
joint years and compared to those with zero joint years. 
Cross-sectional associations between respiratory 
symptoms and joint-year history were examined using 
logistic regression adjusted for age, race, gender, 
FEV1%, current tobacco smoking status, and pack 
years. Pulmonary function testing variables and total 
tissue volume were kept as continuous variables 
and assessed with simple linear regression. Percent-
predicted FEV1 and FVC were adjusted for gender, race, 
height, height2, age, age2, current tobacco smoking 
status, and pack years. All other pulmonary function 
variables were adjusted for height and age in addition 
to the covariates listed above. Current marijuana 
use status was not adjusted for in these analyses to 
examine the effect of joint-year history as the primary 
explanatory variable.
For comparability, emphysema and percent air 
trapping were assessed using the same covariates 
selected for percent emphysema in the previous 
analysis of marijuana use status. Those covariates 
include age, gender, race, FEV1%, tobacco smoking 
status, pack years, and BMI.
Respiratory Symptoms
Neither current nor former marijuana use was 
associated with increased risk for cough, wheeze, or 
chronic bronchitis when compared to never marijuana 
users after adjusting for covariates (Figure 1). 
Respiratory Symptoms: Analysis of Joint-Year History
Cross-sectional analyses were performed to investigate 
associations of number of joint-year categories with 
respiratory symptoms (Online Supplement: Figure 
1b). Those with either 10-20, or greater than 20 joint-
year history were more likely to report wheeze (OR: 
2.27, 1.09-5.39; RR: 1.66, 1.04-2.76) when compared 
to those with zero joint years. Chronic bronchitis was 
associated with those who had a greater than 20 joint-
year history (OR:1.69, 1.19-2.39) when compared 
to those with zero joint years after adjustment for 
covariates. 
Airflow Obstruction and Emphysema
Current and former marijuana smokers had 
significantly higher FEV1 (P<0.001, P<0.001), FEV1% 
(P<0.001, P<0.001), FVC (P<0.001, P<0.001), and 
FVC% (p<0.001, P<0.001) when compared to never 
users, even after adjustment for other predictive 
variables (Table 2). Current marijuana use was 
associated with a significantly higher FEV1/FVC ratio 
(P<0.001) when compared to never users when adjusting 
for other predictive variables. Both current and former 
marijuana use was associated with significantly less 
quantitative emphysema (P=0.004 and P=0.03) and 
increased total tissue volume (P=0.003) compared to 
never users, even after adjusting for age, race, gender, 
FEV1%, current tobacco smoking status, pack years, 
and BMI (Figure 2). Former marijuana users showed 
higher percent air trapping (P<0.001) while current 
use was not significantly different (P=0.61) when 
compared to never marijuana users. 
Airflow Obstruction and Emphysema: Analysis of 
Joint Years
Those with greater than 20 joint years had 
significantly higher FVC (p<0.01), FEV1 (P<0.05), 
and FVC% (p<0.01) when compared to those with zero 
joint years, even after adjustment for other predictive 
variables (online supplement: Table 2b). Those with 10-
20 joint years had significantly higher FVC (P<0.01), 
and FVC% (P<0.05) when compared to those with zero 
joint years. A history of 0-10 joint years was associated 
with higher FVC (P<0.05), and FVC% (P<0.05) when 
compared to those with zero joint years. Percent air 
trapping was significantly higher among those with 
0-10 (P<0.05) and 10-20 (P<0.01) joint years when
compared to those with zero joint years.
Combined Use of Marijuana and Tobacco on 
Lung Health
The effect of combined marijuana use with current 
tobacco smoking on lung function was further assessed 
by stratifying on current smoking status (Figure 3). 
After adjusting for covariates, both current tobacco 
alone and marijuana use alone resulted in a significant 
positive association with FEV1 (P<0.001, P<0.001), 
FEV1% (P<0.001, P<0.001), FVC (P=0.07, P<0.001), 
FVC% (P<0.001, P<0.001) and FEV1/FVC (P<0.001, 
P<0.001), respectively, when compared to those 
smoking neither tobacco nor marijuana. Combined use 
of marijuana and tobacco showed a significant positive 
association with FEV1 (P=0.02), FEV1% (P=0.02), 
FVC (P=0.04), and FVC% (P=0.04) when compared to 
those who did not currently use tobacco or marijuana. 
FEV1/FVC was not significantly different for combined 
current use of tobacco and marijuana (P=0.09) 
compared to non-current smokers of either substance 
at enrollment after adjustment for covariates.
This cross-sectional analysis of the association of 
marijuana history with measures of lung health is one 
of the first12 to include predominantly older adults and 
one of only a few studies that included a quantitative 
assessment of emphysema using CT scans.6,13 It 
is notable that nearly half (49%) of the SPIROMICS 
cohort reported a history of marijuana smoking, 
although only 7% were considered active smokers. 
Similar to previously published studies, we find that 
marijuana smokers were more likely to be male and 
younger than non-users.18,19 Evidence for increase 
of cough, wheeze, and bronchitis among marijuana 
users varies in previously published studies6–8,12,20; 
however most show an increase in symptoms of 
chronic bronchitis in association with marijuana
use.5–9,20,21 We did not find that a history of marijuana 
use is associated with more wheezing, coughing, or 
bronchitis even after considering tobacco cigarette 
smoking. We did, however, find an increase in reported 
wheeze among those with a history of greater than 10 
and 20 joint years. In agreement with other published 
studies,6,7,12,21,22 we also did not find that marijuana 
use was associated with more obstructive lung disease, 
but instead found an association between marijuana 
use and a higher FEV111 and FVC.10-12,23
Although not all published studies are in agreement, 
one of the more consistent lung function findings in 
marijuana literature is a higher FVC.10–12,22 While 
the mechanism for this is not clear, it could include 
deeper breathing of marijuana users.2,23 If FEV1 is 
held constant, a higher FVC would be expected to be 
associated with a lower FEV1/FVC, which could result in 
classification as mild obstruction. Interaction between 
marijuana and tobacco shows conflicting results; while 
one study found a synergistic effect of marijuana and 
tobacco such that marijuana when smoked along with 
tobacco augmented the impact of tobacco on the 
prevalence of COPD,12 there is opposing evidence to 
suggest that the effect of marijuana is to reduce the 
effect of tobacco on adverse pulmonary function.6 
In SPIROMICS, lung function among combined 
tobacco and marijuana users was lower compared to 
non-smokers of either substance after adjusting for 
covariates. These results should be interpreted with 
caution since in this population, adults who have quit 
smoking tobacco or marijuana likely did so because of 
poorer health. 
Discussion
use status and pulmonary outcomes. Finally, marijuana 
and its effect on lung function was not the primary 
aim of the SPIROMICS study and there were only 
192 active users. Although these results were able to 
detect differences in lung function and phenotypes 
among marijuana use groups, these results are not 
generalizable to a healthy adult population. There 
may be no to little increased risk of marijuana use for 
a further increase in respiratory symptoms or adverse 
effects on lung function among those with a history of 
concomitant tobacco use.
This cross-sectional analysis of participants enrolled 
into the SPIROMICs cohort was performed to 
investigate the relationships between marijuana use 
and pulmonary function and symptoms. Those enrolled 
were carefully screened and recruited based on tobacco 
use history and spirometric function and therefore, 
do not represent a random population of adults. 
Additionally, those included in this analysis reported 
>20 pack-year history of tobacco use. The relationships 
we found between tobacco use and pulmonary
outcomes agree with a large body of research on the
adverse pulmonary consequences of tobacco smoking
(results not reported here). In contrast to tobacco
smoking exposure, the illegality of marijuana use, up
until recent years in select geographic areas, has made
it a difficult target of epidemiologic observation. This
study collected usage information on marijuana and
reports on prevalence and associations of marijuana
use among an older adult population with a history of
heavy smoking, and lung health outcomes.
Previously reported findings of marijuana and 
pulmonary symptoms have led to conflicting 
conclusions. Our results indicate increased FEV1 and 
FVC among current and former users of marijuana 
even after controlling for other predictive variables. 
Evidence for a decreased ratio of FEV1/FVC with 
marijuana use has been supported8,9,26,27 but could 
be due to an increased FVC.9,26,27  This study also 
revealed a lower percentage of emphysema, yet a 
higher total tissue volume among current and former 
marijuana users and a higher percentage of air trapping 
among former users after adjustment for covariates. 
Percentage of emphysema and total tissue volume 
are inversely related; increased inflammation could 
explain these associations in our population. Analyses 
Conclusion
There are also case series reporting lung bullae 
formation in marijuana smokers.23,24 While Aldington 
et al noted significantly greater lung attenuation in 
lung slices at the apices on CT scans in marijuana 
smokers derived from a random sample of residents of 
Wellington, New Zealand, they showed no significant 
increase of macroscopic emphysema on CT in their 
marijuana smokers.6 In agreement with these findings, 
our study found no evidence for increased extent of 
quantitatively scored emphysema in marijuana users 
nor any evidence of bullae.6,25 
There are limitations to the interpretation of the 
results from this study.  Mainly, this population is 
non-random and was recruited based on tobacco 
smoking history. Although we adjusted for tobacco 
use and excluded never tobacco smokers, it is still 
unclear if long-term heavy marijuana smoking 
results in significant risk of respiratory symptoms, 
lung obstruction, inflammation, or emphysema. The 
strong associations between tobacco smoking and 
adverse respiratory health may be masking effects 
of marijuana use. However, contemporaneous to the 
legalization of marijuana in many states, there has 
also been an exponential increase in the potency of 
tetrahydrocannabinol (THC) in marijuana from 3% to 
now 30% or more. Thus, marijuana smoke exposure 
should be expected to decrease as potency increases 
since users would need to smoke less to achieve the 
desired level of intoxication. Moreover, there may be 
fewer individuals who have heavy marijuana smoking 
exposure, unlike many tobacco smokers for whom it 
is not uncommon to smoke 40-60 cigarettes per day. 
Another limitation is that marijuana was an illegal, 
schedule 1 substance in most of the United States at 
the time our participants were recruited. This may have 
biased against honest disclosure of marijuana use. 
Additionally, marijuana exposure can be more difficult 
to quantify because of sharing, differences in dosing 
and inhalation techniques, and methods to consume 
or use marijuana (e.g., vaping, dabbing, edibles). These 
newer methods of exposure may not have been fully 
quantified in the SPIROMICS cohort; however, the 
advanced age of the cohort suggests that smoking 
was the predominant marijuana delivery method.18,19 
The analyses presented here adjust for joint years. It is 
difficult to quantify joint years since one joint or bowl 
is not universally comparable. This may explain why 
joint years was not shown to be a predictive covariate 
in any of our statistical models of current marijuana 
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of an interaction between marijuana and tobacco 
smoking revealed increases in FEV1 and FVC among 
those who used marijuana only, tobacco only, and 
both marijuana and tobacco. These results are likely 
heavily biased and should be interpreted with caution. 
Those who quit smoking tobacco likely did so because 
of poorer health; contrary to those who continued to 
smoke tobacco. Among older adults with a history of 
tobacco use, marijuana use does not appear to increase 
risk for adverse lung function. It is necessary to collect 
more epidemiologic data on marijuana exposure in 
a broader population to better understand its health 
consequences. 
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